Optimising the therapeutic efficacy of anti-inflammatory macrophages for use in chronic kidney diseases

优化抗炎巨噬细胞在慢性肾脏疾病中的治疗效果

• 批准号: nhmrc : 632665
• 负责人: Dr Yiping Wang
• 金额: $ 40.35万
• 依托单位: The University of Sydney
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2010
• 资助国家: 澳大利亚
• 起止时间: 2010-01-01 至 2013-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/optimising-therapeutic-efficacy-kidney-diseases/98583
• 关键词: Optimising; therapeutic; efficacy; anti; inflammatory

Chronic kidney disease (CKD) is a major cause of death and morbidity in Australia. Current treatments that are able to delay progression for CKD are limited. As a consequence, more than 2300 additional Australians need kidney replacement each year and many more die of kidney failure. We have reduced and prevented injury in a mouse model of CKD by administering protective white blood cells - macrophages. This project will modify macrophages ex vivo to optimize them for use as a therapy for CKD.

慢性肾脏疾病(CKD)是澳大利亚人死亡和发病的主要原因。目前能够延缓慢性肾脏病进展的治疗方法是有限的。因此，每年有超过2300名澳大利亚人需要肾脏置换，更多的人死于肾衰竭。我们已经通过给予保护性白细胞-巨噬细胞来减少和防止CKD小鼠模型的损伤。该项目将在体外对巨噬细胞进行修饰，以优化它们作为CKD的治疗方法。